ULARITIDE ( DrugBank: Ularitide )


1 disease
IDDisease name (Link within this page)Number of trials
86Pulmonary arterial hypertension1

86. Pulmonary arterial hypertension


Clinical trials : 1,181 Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-004815-29-DE
(EUCTR)
04/08/202110/03/2021A phase 2 study to investigate the effects on the blood flow induced by step-wise increased doses of intravenously administered ularitide in patients suffering from pulmonary arterial hypertensionOpen-label, dose escalation study of ularitide for the investigation of hemodynamic effects in patients with pulmonary arterial hypertension (UPAH) Pulmonary arterial hypertension
MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: Ularitide
INN or Proposed INN: ULARITIDE
Other descriptive name: Urodilatin
Cardiorentis AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
10Phase 2Germany